TFC Business Summary

Taipei Fertility Center (TFC), listed as 4738.TWO on the Taipei Exchange, operates as a premier provider of Assisted Reproductive Technology (ART) services in Taiwan. The company generates revenue through a service-based model encompassing high-margin fertility treatments, including In Vitro Fertilization (IVF), Artificial Insemination by Husband (AIH), and comprehensive laboratory services such as egg and sperm cryopreservation and genetic screening. TFC distinguishes itself through a high-specification, billion-level (TWD) embryology laboratory and a patient-centered digital platform that integrates telemedicine and precision treatment tracking. Within the competitive landscape, TFC maintains a leading market position characterized by a 70% success rate for patients under 38, competing directly with major institutions such as Lee Women's Hospital, Taiwan IVF Group, and the reproductive centers of Mackay Memorial Hospital and Taipei Medical University Hospital. TFC was founded and is currently led by Dr. Chii-Ruey Tzeng, a globally recognized pioneer often cited as the "Father of IVF" in Taiwan for successfully cultivating the nation's first IVF baby in 1985. Dr. Tzeng brings an elite academic pedigree, holding a Master of Public Health from Harvard University and completing his fellowship at Brigham and Women's Hospital, Harvard Medical School. The executive leadership and "Golden Medical Team" include senior chief physicians such as Dr. Shun-Jen Tan and Dr. Ian Chang, supported by a specialized staff of over 100 professionals. The company's board and strategic direction are heavily influenced by its clinical excellence, as evidenced by its status as the only reproductive clinic in Taiwan to receive the Symbol of National Quality (SNQ) certification for multiple consecutive years.